6 completed, 2 active not recruiting, 2 recruiting, 1 not yet recruiting. 7 Phase 2, 4 Phase 1, 1 Early Phase 1, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 3, Active not recruiting 2, Recruiting 2 |
| Phase 1 | 4 | Completed 1, Not yet recruiting 1, Recruiting 1, Terminated 1 |
| Early Phase 1 | 1 | Completed 1 |
| Not applicable | 1 | Completed 1 |
Follow Skin Squamous Cell Carcinoma: new trials by email Literature Review of Skin Squamous Cell Carcinoma trials Research Report on Skin Squamous Cell Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Intratumoral Injection of Standard Universal Donor Expanded Natural Killer Cells and TGF-beta Imprinted Natural Killer Cells for the Treatment of Skin Squamous Cell Carcinoma and Basal Cell Carcinoma Biopsy Procedure, Natural Killer Cell Therapy, Surgical Procedure - Skin Basal Cell Carcinoma, Skin Nodular Basal Cell Carcinoma | Early Phase 1 | Completed | Ohio State University Comprehensive Cancer Center | 4 | 2025-10-16 | 2026-09-28 |
| NIFR Image-guided Surgery for Malignant Soft Tissue Tumor With Low-dose SWIG Technique ICG administration - Dermatofibrosarcoma Protuberans (DFSP), Skin Squamous Cell Carcinoma | Phase 1 | Not yet recruiting | The Plastic Surgery Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College | 592 | 2024-10-30 | 2024-09-24 |
| EMLA Topical Cream for Treatment of Pain in Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigraphy for Skin Cancers Eutectic Mixture of Local Anesthetics, Placebo Administration, Questionnaire Administration - Cutaneous Melanoma, Merkel Cell Carcinoma | Phase 2 | Recruiting | Ohio State University Comprehensive Cancer Center | 100 | 2023-12-19 | 2026-03-10 |
| Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors Cyclophosphamide, Neoantigen Peptide Vaccine, Pembrolizumab - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 | Phase 1 / Phase 2 | Recruiting | Mayo Clinic | 138 | 2022-03-31 | 2026-08-20 |
| Avelumab With or Without Cetuximab in Treating Patients With Advanced Skin Squamous Cell Cancer Avelumab, Cetuximab - Skin Squamous Cell Carcinoma, Metastatic Skin Cancer | Phase 2 | Active not recruiting | Alliance for Clinical Trials in Oncology | 60 | 2019-06-17 | 2026-06-02 |
| Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors Nanrilkefusp alfa, Pembrolizumab - Thyroid Cancer, Renal Cell Carcinoma | Phase 1 | Terminated | SOTIO Biotech AG | 115 | 2019-06-13 | 2026-03-27 |
| ACCEPTABILITY AND WRITING FREQUENCY OF ADVANCED DIRECTIVES IN ONCO-DERMATOLOGY PATIENTS no intervention, only complete a survey - Advance Directives, Oncology | Unknown | Central Hospital, Nancy, France | 150 | 2019-01-21 | 2019-01-30 | |
| Alpha Radiation Emitters Device for the Treatment of Squamous Cell Carcinoma (DaRT) Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT) - Skin Squamous Cell Carcinoma | Not applicable | Completed | Alpha Tau Medical LTD. | 28 | 2017-11-21 | 2021-03-10 |
| Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers Biopsy Procedure, Biospecimen Collection, Computed Tomography - Anaplastic Large Cell Lymphoma, ALK-Negative, Anaplastic Large Cell Lymphoma, ALK-Positive | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 68 | 2017-09-27 | 2026-08-13 |
| Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors Atezolizumab, Cobimetinib - Skin Squamous Cell Carcinoma, Appendix Adenocarcinoma | Phase 2 | Completed | M.D. Anderson Cancer Center | 49 | 2017-04-07 | 2025-05-28 |
| Pembrolizumab in Patients With Locally Advanced or Metastatic Skin Cancer Pembrolizumab - Recurrent Skin Carcinoma, Skin Squamous Cell Carcinoma | Phase 2 | Completed | Emory University | 11 | 2017-01-27 | 2024-06-26 |
| Oral Rigosertib for Squamous Cell Carcinoma rigosertib - Head and Neck Squamous Cell Carcinoma, Anal Squamous Cell Carcinoma | Phase 2 | Completed | Traws Pharma, Inc. | 64 | 2013-03-01 | 2017-06-26 |
| Phase Ib Study of Erlotinib Prior to Surgery in Patients With Head and Neck Cancer Erlotinib Hydrochloride, Laboratory Biomarker Analysis - Recurrent Head and Neck Carcinoma, Recurrent Salivary Gland Carcinoma | Phase 1 | Completed | M.D. Anderson Cancer Center | 48 | 2009-08-05 | 2025-09-05 |
Carcinoma, Merkel Cell (4) · Melanoma (4) · Carcinoma, Basal Cell (3) · Squamous Cell Carcinoma of Head and Neck (3) · Anus Neoplasms (2) · Carcinoma, Hepatocellular (2) · Carcinoma, Non-Small-Cell Lung (2) · Carcinoma, Renal Cell (2) · Lymphoma, T-Cell, Cutaneous (2) · Neoplasm Metastasis (2) · Neoplasms (2) · Skin Neoplasms (2) · Triple Negative Breast Neoplasms (2) · Uterine Cervical Neoplasms (2) · Adenocarcinoma, Mucinous (1)
Neoplasms (9) · Neoplasms by Histologic Type (9) · Carcinoma (8) · Neoplasms by Site (8) · Neoplasms, Glandular and Epithelial (8) · Skin Diseases (6) · Skin and Connective Tissue Diseases (6) · Adenocarcinoma (5) · Neoplasms, Germ Cell and Embryonal (5) · Neoplasms, Nerve Tissue (5) · Neuroectodermal Tumors (5) · Neuroendocrine Tumors (5) · Carcinoma, Neuroendocrine (4) · DNA Virus Infections (4) · Infections (4)
Biopsy (3) · pembrolizumab (3) · Specimen Handling (2) · Cetuximab (1) · Colony-Stimulating Factors (1) · Cyclophosphamide (1) · Erlotinib Hydrochloride (1) · Immunoglobulin G (1) · Lidocaine, Prilocaine Drug Combination (1) · Magnetic Resonance Spectroscopy (1) · Nivolumab (1) · ON 01910 (1) · Surgical Procedures, Operative (1) · X-Rays (1) · atezolizumab (1)
M.D. Anderson Cancer Center (2) · Ohio State University Comprehensive Cancer Center (2) · Alliance for Clinical Trials in Oncology (1) · Alpha Tau Medical LTD. (1) · Central Hospital, Nancy, France (1) · Emory University (1) · Mayo Clinic (1) · National Cancer Institute (NCI) (1) · SOTIO Biotech AG (1) · The Plastic Surgery Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (1) · Traws Pharma, Inc. (1)
United States (10) · France (2) · Czechia (1) · Italy (1) · Spain (1)
Carlo M Contreras, MD (1) · Dan P. Zandberg, MD (1) · Kanwal P Raghav (1) · Kirsten Johnson, MD (1) · Michael Kurman, MD (1) · Michael Lowe, MD, MA (1) · Stephane Champiat, Dr. (1) · Xiuning Le (1) · Yanyan Lou, MD, PhD (1)
2018 (1), P30CA138292 (1), U10CA180821 (1), UM1CA186709 (1), UM1CA186716 (1)